Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Becton, Dickinson and Company

Market Cap 40.72B 35.34B 32.57B 30.52B 57.03B 3,899B 58.22B 389B 150B 1,880B 153B 150B 6,535B P/E Ratio 2026 *
36.8x
P/E Ratio 2027 * 28.2x
Enterprise Value 56.68B 49.18B 45.34B 42.48B 79.37B 5,427B 81.03B 541B 209B 2,616B 213B 208B 9,096B EV / Sales 2026 *
2.95x
EV / Sales 2027 * 2.78x
Free-Float
74.04%
Yield 2026 *
2.61%
Yield 2027 * 2.66%
Manager TitleAgeSince
Chief Executive Officer 53 28/01/2020
Director of Finance/CFO 44 05/12/2025
Compliance Officer - 01/02/2023
Director TitleAgeSince
Director/Board Member 75 24/09/2002
Director/Board Member 71 26/07/2010
Chairman 53 28/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-18.36% - - 40.72B
+0.67%-0.97%-33.55%-11.34% 155B
+0.28%-1.67%-8.51%-4.41% 103B
+0.69%+5.01%-0.97%+58.30% 54.72B
-0.23%-6.71%+50.66%+49.87% 53.65B
+0.19%+6.62% - - 30.9B
+0.71%+3.76%-9.24%-40.65% 28.85B
-0.05%+3.85%+47.11%-7.79% 23.38B
-1.93%-0.66%-14.31%+2.17% 21.22B
-0.08%-2.00%-13.60%+0.05% 20.31B
Average +0.01%+2.31%+2.20%+5.77% 54.6B
Weighted average by Cap. +0.26%+2.22%-6.88%+5.09%

Financials

2026 *2027 *
Net sales 19.21B 16.67B 15.36B 14.39B 26.9B 1,839B 27.46B 183B 70.95B 886B 72.1B 70.54B 3,082B 19.72B 17.11B 15.77B 14.78B 27.61B 1,888B 28.19B 188B 72.84B 910B 74.01B 72.42B 3,164B
Net income 1.12B 976M 900M 843M 1.57B 108B 1.61B 10.73B 4.15B 51.91B 4.22B 4.13B 180B 1.46B 1.27B 1.17B 1.1B 2.05B 140B 2.09B 13.95B 5.4B 67.46B 5.49B 5.37B 235B
Net Debt 15.95B 13.85B 12.76B 11.96B 22.34B 1,528B 22.81B 152B 58.94B 736B 59.89B 58.6B 2,560B 14.07B 12.21B 11.26B 10.55B 19.71B 1,347B 20.12B 134B 51.99B 650B 52.83B 51.69B 2,258B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!